For example, in 2003 GE licensed a broad class of imaging compounds from the University of Pittsburgh that attach to beta-amyloid plaque in the brain, allowing the plaque that causes Alzheimer's disease to be imaged with PET. Current clinical trials involve using these compounds to measure the levels of beta-amyloid plaque and to potentially measure the effectiveness of drug therapies being developed to combat Alzheimer's disease as early as possible.

"Early diagnosis of disease cannot be achieved through technology alone - biology and chemistry are key to early disease detection and treatment," said Hogan. "This intersection of biochemistry and technology will help translate information into earlier diagnosis. GE has the expertise, broad product portfolio, and the imagination to bring this new 'early health' model of care to fruition."

Back to HCB News

More Industry Headlines